Sol-Gel Technologies Net Change in Short-term Investments 2016-2024 | SLGL
Sol-Gel Technologies net change in short-term investments from 2016 to 2024. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
Sol-Gel Technologies Annual Net Change in Short-term Investments
(Millions of US $) |
| 2024 |
$16 |
| 2023 |
$-11 |
| 2022 |
$-7 |
| 2021 |
$20 |
| 2020 |
$19 |
| 2019 |
$16 |
| 2018 |
$-57 |
| 2017 |
$N/A |
| 2016 |
$N/A |
| 2015 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.021B |
$0.012B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
